Interleukin-11 compositions and methods of use
A technology of interleukin and composition, which is applied in the pharmaceutical composition for preventing and/or treating thrombocytopenia, and relieves the field of individual thrombocytopenia, which can solve the problems of enhancing, limiting beneficial effects, increasing cancer incidence and mortality, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0166] Example 1: Effect of IL-11 on CMC-544-Induced Thrombocytopenia in Nude Mice
[0167] experimental design:
[0168] In this example it is shown that IL-11( ) on CMC-544-induced thrombocytopenia. Initial IL-11 dosing was daily intraperitoneal administration (250 μg / kg) starting two days before CMC-544 administration, or twice daily (125 μg / kg) starting 8 hours after CMC-544 administration (considered day 0) . IL-11 was administered daily for 8 days after CMC-544 administration. Mice were bled on day 0 to obtain baseline platelet values and then either vehicle or CMC-544 was administered ip at 4 μg per mouse. Higher or lower doses of CMC-544 were also administered. Blood samples were taken at various time points 3 days after drug administration.
[0169] method:
[0170] A 25-gauge needle was inserted into the tail vein of the mouse and then withdrawn to allow the blood droplet to ooze out. A 5 μL blood sample was collected for analysis. Platelet values were ...
Embodiment 2
[0172] Example 2: Effect of IL-11 on CMC-544-induced Thrombocytopenia in Monkeys
[0173] A - first study
[0174] Test design:
[0175] On day -9, blood was taken from 10 monkeys (cynomolgus monkeys) from which 8 monkeys with more normal blood values were selected for the study. The selected monkeys were divided into 2 groups, 4 in each group. A group of test monkeys were pre-administered IL-11 for 5 days before receiving CMC-544. Another group of monkeys (or control monkeys) is administered a sterile saline vehicle control. This provides an appropriate control for the stress involved in administering IL-11 to monkeys in order to differentiate potential vehicle and / or IL-11 side effects (i.e. effects on blood or hematological parameters), should they occur . Both groups received CMC-544 on Day 1. IL-11 was administered to the test group on the day of CMC-544 administration, and continued for 4 days. The test group received a total of 10 doses of IL-11. Both groups o...
Embodiment 3
[0219] Example 3: Effect of calicheamicin conjugates on platelet levels in mice
[0220] experimental design:
[0221] On day 0, mice were bled to obtain baseline platelet values. Mice were then administered vehicle, CMC-544 or other calicheamicin conjugates intravenously or intraperitoneally (4 μg per mouse). Higher or lower dosages may also be administered. Blood samples were taken at 72 hours (Day 3), 96 hours (Day 4) and 168 hours (Day 8) after drug administration.
[0222] method:
[0223] A 25-gauge needle was inserted into the tail vein of the mouse and then withdrawn to allow the blood droplet to ooze out. A 5 μL blood sample was collected for analysis. Blood was sampled on day 0 before drug administration, and on days 3, 4, and 8, for a total of 4 collections of 5 μL each (20 μL in total).
[0224] Dosing: CMC-544 or other calicheamicin conjugates were administered once at a dose of 4 μg calicheamicin DMH intraperitoneally or intravenously. The dose volume for an...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com